2023
DOI: 10.1016/j.pharmthera.2023.108500
|View full text |Cite
|
Sign up to set email alerts
|

Vasospastic angina: Past, present, and future

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 231 publications
0
1
0
Order By: Relevance
“…Both DHP and non-DHP CCBs have been proven to reduce the frequency and intensity of angina episodes along with the occurrence of MI and life-threatening arrhythmias [ 143 , 144 , 145 , 146 ]. A recent meta-analysis found that benidipine, a second-generation of DHP CCB with high affinity for the coronary vessels, might be the most effective CCB for improving both symptoms control and outcomes [ 147 ].…”
Section: Therapymentioning
confidence: 99%
“…Both DHP and non-DHP CCBs have been proven to reduce the frequency and intensity of angina episodes along with the occurrence of MI and life-threatening arrhythmias [ 143 , 144 , 145 , 146 ]. A recent meta-analysis found that benidipine, a second-generation of DHP CCB with high affinity for the coronary vessels, might be the most effective CCB for improving both symptoms control and outcomes [ 147 ].…”
Section: Therapymentioning
confidence: 99%